Showing 176–200 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Ding X, Du W, Liu Q, Tao L, Shao Y, et al.
…PPD, and EC tests. In the second stage, to evaluate whether BCG vaccination affected the efficacy of skin tests, the participants with three negative results in the first stage were randomly assigned to the BCG and placebo groups at a ratio of 2:1 and underwent three tests. The p…
Joan Joseph-Munné, Milena Maya-Hoyos, Narcís Saubi, Santiago Perez, Miguel Angel Martinez Lopez, et al.
…Thus, the development of an effective, safe, and accessible vaccine for neonates and/or adults is an urgent need to prevent or control HIV infection or progression to AIDS. An effective HIV vaccine should induce long-lasting mucosal immunity, broadly neutralizing antibodies, inna…
Hernandez-Pando R, Shin SJ, Clark S, Casonato S, Becerril-Zambrano M, et al.
…he major threats to global human health. The only available vaccine ( Mycobacterium bovis BCG) protects children from disseminated forms of TB but does not effectively protect adults from the respiratory form of the disease, making the development of new and more-efficacious vacc…
Enriquez AB, Izzo A, Miller SM, Stewart EL, Mahon RN, et al.
…f death worldwide due to a single infectious disease agent. BCG, the only licensed vaccine against TB, offers limited protection against pulmonary disease in children and adults. TB vaccine research has recently been reinvigorated by new data suggesting alternative administration…
Schrager LK, Vekemens J, Drager N, Lewinsohn DM, Olesen OF
…imelines to control the spread of the disease require a new vaccine capable of preventing tuberculosis, particularly in adolescents and adults. The spread of strains resistant to multiple drugs adds additional urgency to the vaccine development effort yet attempts to develop new …
Watt J, Liu J, Liu J
…B and 1.45 million deaths in 2018. Bacille Calmette-Guérin (BCG) remains the only approved vaccine for Mycobacterium tuberculosis ( M. tb , causative agent of TB), however clinical studies have shown BCG has variable effectiveness ranging from 0-80% in adults. With 1.7 billion pe…
Jeyanathan M, Xing Z
…obal health concerns. There has been a lack of an effective vaccine strategy. The Bacillus Calmette-Guerin (BCG), the only licensed vaccine against TB, is not effective against adult pulmonary TB, the highly contagious form of TB. In the past two decades or so, many novel TB vacc…
Runlin Wang, Xiaochun Wang, Lingyun Kong, Qishan Sun, Jiagao Wu, et al.
…terium tuberculosis (M. tb). Bacillus Calmette-Guérin (BCG) is currently the only approved vaccine for TB prevention; however, its protective efficacy against tuberculosis in adults is limited. To overcome the limitations of BCG, recombinant plasmids were constructed and exp…
Scriba TJ, Netea MG, Ginsberg AM
…loyment of standard drug regimens, modern diagnostics and a vaccine (bacille Calmette Guerin, BCG), the global tuberculosis epidemic is inadequately controlled. Novel, effective vaccine(s) are a crucial element of the World Health Organization End TB Strategy. TB vaccine research…
Chugh S, Bahal RK, Dhiman R, Singh R
…he risk of TB is immunization with bacilli Calmette-Guerin (BCG). Although BCG has been widely used to protect against TB, reports show that BCG confers highly variable efficacy (0-80%) against adult pulmonary TB. Unwavering efforts have been made over the past 20 years to develo…
A. L. A. Leite, A. S. M. dos Santos, A. C. L. G. Silva, S. M. Arruda
… 10.6 million new cases in 2021. Bacillus Calmette-Guérrin (BCG) is the only licensed vaccine against TB, despite its variable efficacy (0-80%) against the pulmonary from of the disease in adults. Recent clinical trials indicate the importance of exploring diverse classes of anti…
Robyn M. Jong, Erik Van Dis, Xammy Nguyenla, Alexander Baltodano, Gabrielle Pastenkos, et al.
Abstract The only licensed vaccine for tuberculosis, Mycobacterium bovis Bacille Calmette-Guérin (BCG), is not reliably effective against adult pulmonary tuberculosis. A major hurdle to tuberculosis vaccine development is incomplete understanding of successful immunity against th…
Michele Tameris, MD
…TBVAC in South African newborns. Ninety-nine HIV unexposed, BCG naïve newborns will be randomized to receive either BCG 2.5 x 105 CFU (n=24) or MTBVAC at one of three dose levels (n=75). Allocation will be double blind. Enrolment will be sequential into 3 cohorts of increasing MT…
Dongdong Zhang, Donghui Wang, Shuo Jiang, Yue Wan, Yukun Zhao, et al.
…at affects people worldwide. Bacillus Calmette-Guérin (BCG), the only approved TB vaccine, has been shown to have highly variable protective efficacy in different populations and is ineffective at protecting adults. Therefore, the development of more effective TB vaccines is…
Li J, Zhao A, Tang J, Wang G, Shi Y, et al.
Bacillus Calmette-Guérin (BCG) has been in use for nearly 100 years and is the only licensed TB vaccine. While BCG provides protection against disseminated TB in infants, its protection against adult pulmonary tuberculosis (PTB) is variable. To achieve the ambitious goal of eradi…
Larson EC, Ellis-Connell AL, Rodgers MA, Gubernat AK, Gleim JL, et al.
…ficiency virus (HIV). Intra-dermal Bacille Calmette-Guérin (BCG) delivery is the only licensed vaccine against tuberculosis; however, it offers little protection from pulmonary tuberculosis in adults and is contraindicated in people living with HIV. Intravenous BCG confers protec…
Bashar Haruna Gulumbe, Aminu Shehu
…is correspondence underlines the critical role of advancing vaccine research. Historically, the BCG vaccine, developed over a century ago, has been the cornerstone of TB prevention. However, its efficacy is limited, particularly in adults and against pulmonary TB, the most common…
Bull NC, Kaveh DA, Garcia-Pelayo MC, Stylianou E, McShane H, et al.
…use of human mortality from an infectious disease. The only vaccine currently available, bacille Calmette-Guérin (BCG), demonstrates some protection against disseminated disease in childhood but very variable efficacy against pulmonary disease in adults. A greater understanding o…
Abil OZ, Liu S, Yeh YW, Wu Y, Sen Chaudhuri A, et al.
…the top three causes of death. Currently, the only licensed vaccine against TB is the bacillus Calmette-Guerin (BCG), which lacks efficacy in preventing and controlling pulmonary TB in adults. We aimed to evaluate a nasal TB vaccine formulation composed of the Mtb-specific vaccin…
Carlos Martín, Jesús Gonzalo-Asensio, Nacho Aguiló, Ainhoa Arbués
…d ultimately elimination - will remain unachieved without a vaccine capable of preventing pulmonary disease and transmission. Bacille Calmette-Guérin (BCG), a live attenuated vaccine derived from Mycobacterium bovis and the only licensed TB vaccine, has been widely implement…
Zehui Lei, Jing Wang, Cui Hua Liu
… remains a leading burden on global health and the economy. Vaccines represent the most economically effective approach to preventing and controlling infectious diseases. Currently, Bacillus Calmette–Guérin (BCG) is the only available vaccine for TB, which protects infants and yo…
Qian C, Fan X, Wang R, Cao B, Yu J, et al.
…ad use of the Mycobacterium bovis bacillus Calmette-Guerin (BCG) vaccine, the primary factor for the TB pandemic and deaths is adult TB, which mainly result from endogenous reactivation of latent Mycobacterium tuberculosis (MTB) infection. Improved new TB vaccines with eligible s…
Ochran Chetty, Cohen Chetty
…e a global health challenge and currently only one licensed vaccine is available. For nearly 100 years, the Bacillus Calmette-Guérin (BCG) vaccine has been in use. While it provides protection against disseminated TB in infants, its protection against adult and adolescent pulmona…
Szachniewicz MM, Neustrup MA, van den Eeden SJF, van Meijgaarden KE, Franken KLMC, et al.
…ew cases and 1.3 million deaths annually. The only existing vaccine, Mycobacterium Bovis Bacillus Calmette-Guérin (BCG), provides highly variable and inadequate protection in adults and adolescents. This study explores newly developed subunit tuberculosis vaccines that use a mult…
Clark RA, Sumner T, Weerasuriya CK, Bakker R, Scriba TJ, et al.
…upcoming trial may provide further evidence that adolescent/adult-targeted BCG revaccination prevents sustained Mycobacterium tuberculosis infection, but its public health value depends on its impact on overall tuberculosis morbidity and mortality, which will remain unknown. Usin…